The COVID-19 vaccines available in the United States have evolved significantly since their initial rollout. For people aged 65 and older, understanding which vaccines exist and how they differ has become an important part of making informed health decisions. As of 2024, older adults have access to several vaccine options that were developed specifically with their immune systems in mind.
Learn About Paying Your FGUA Bill Online →
The vaccines currently authorized for use fall into different categories based on their formulation. The original formulations targeted the original strain of COVID-19, while newer versions address variants that have circulated more recently. The CDC and manufacturers have updated these formulations based on which virus variants are most common at different times of the year. This is similar to how the flu vaccine changes annually to match circulating strains.
For seniors, this matters because research shows that older immune systems respond differently to vaccines than younger ones. Clinical trials specifically tested how well vaccines worked in people over 65, with results showing strong protection against severe illness and hospitalization in this age group. The data from millions of vaccine doses given to seniors since 2020 has helped establish clear safety patterns in people this age.
Multiple manufacturers produce COVID vaccines, including Pfizer-BioNTech, Moderna, and Johnson & Johnson. Each manufacturer uses different technology platforms, though all have undergone rigorous safety testing. The vaccine landscape you'll encounter today looks different than it did two years ago—fewer options exist, but the ones available have been refined based on real-world experience with older populations.
Practical takeaway: Before diving into which vaccine to choose, understand that today's options have been studied extensively in seniors and represent several years of refinement. The vaccines available now are not experimental—they have safety data from millions of older adults.
When COVID vaccines first became available in late 2020 and early 2021, they targeted the original strain that emerged in Wuhan, China. As the pandemic continued, the virus mutated. New variants like Delta and Omicron spread through the population, and scientists realized the original vaccine formulations were becoming less effective at preventing infection with these new versions. However, the vaccines continued to prevent severe illness and death, which remained the primary goal.
Free Guide to Pay by Plate Illinois Billing →
In response, vaccine manufacturers developed "bivalent" and then "monovalent" updated formulations. A bivalent vaccine contained genetic instructions for two different virus versions—the original strain plus one or more newer variants. These became available in 2022 as a booster option for people who had already received the original vaccines. The thinking was that protecting against multiple versions would offer broader protection as variants continued to circulate.
By 2023 and 2024, the approach shifted again. After studying how the virus was actually circulating and how people's immune systems responded, manufacturers created monovalent vaccines targeting a single, more current variant. Depending on the time of year, this might be an Omicron subvariant like XEC or JN.1. The logic here is similar to flu vaccines: the shot targets the strain most likely to circulate during the upcoming season.
For seniors specifically, these formulation changes matter because older adults often have weaker immune responses to vaccines overall. A vaccine that more closely matches the virus circulating in your area during the season when you're most likely to encounter it may provide better protection. Additionally, seniors are more likely to experience severe COVID illness if infected, making a well-matched vaccine particularly valuable.
The vaccines undergo testing for safety after each formulation change, with particular attention to how they perform in people over 65. Data from pharmacies, clinics, and hospitals that administer these vaccines continue to be monitored for any safety signals. This ongoing surveillance is one reason formulation recommendations can change—if data suggests better outcomes with one approach over another, that information gets incorporated into recommendations.
Practical takeaway: The vaccine you received two years ago and the one currently recommended may not be identical. Understanding that vaccines have been updated based on circulating variants helps you understand why your doctor might suggest a new dose rather than relying solely on previous vaccination.
As of 2024, three manufacturers produce COVID vaccines distributed in the United States: Pfizer-BioNTech, Moderna, and Janssen (Johnson & Johnson). Each has different characteristics worth understanding, especially if you're deciding which one to receive or wondering whether switching from your previous vaccine makes sense.
Free Guide to Mold Removal Methods for Walls →
Pfizer-BioNTech vaccines use messenger RNA (mRNA) technology. The vaccine contains genetic instructions that teach your cells to make a protein that looks like part of the COVID virus. Your immune system then responds to this protein. Pfizer vaccines are administered as two-dose series for initial vaccination, followed by boosters. Clinical trials in seniors showed about 95% effectiveness against severe illness when the vaccines were first released, though this protection declined gradually over months, which is why boosters became recommended. The Pfizer vaccine is stored at ultra-cold temperatures, though this isn't relevant for people receiving the shots—storage is handled by providers.
Moderna vaccines use the same mRNA technology but with different dosing amounts and timing. Initial trials showed similar effectiveness to Pfizer in older adults—around 94-95% against severe disease. Moderna doses are higher than Pfizer doses, which some research suggests might provide slightly longer-lasting immunity in some people, though both vaccines ultimately require boosters over time. Like Pfizer, Moderna requires multiple doses for initial vaccination but has evolved to offer single updated doses in recent years.
Janssen (Johnson & Johnson) uses a different technology platform called viral vector technology. Instead of mRNA, this vaccine uses a modified virus to deliver genetic instructions to your cells. A key difference is that the original Janssen vaccine was a single dose, rather than two. However, data showed that seniors receiving Janssen benefited significantly from boosters, making it more comparable to Pfizer and Moderna in terms of the total number of shots needed for sustained protection. Janssen is less commonly used now than earlier in the pandemic, with fewer updated formulations available.
In practice, all three vaccines show similar real-world outcomes in preventing hospitalization and death from COVID in people over 65. Published data from large healthcare systems tracking thousands of seniors shows that vaccine effectiveness against these severe outcomes is comparable across manufacturers. Where they differ is in logistical factors (how many doses, how often), storage requirements, and specific side effect profiles. Some people tolerate one better than another, which is another legitimate factor in choosing.
Practical takeaway: There is no "best" vaccine for all seniors—the main differences come down to logistics, how your own body typically responds to vaccines, and what's available where you live. The most important factor is receiving an updated formulation appropriate for the current year, regardless of manufacturer.
One of the most confusing aspects of COVID vaccination for older adults is understanding when to get vaccinated and how often. This has changed multiple times since vaccines first became available, and recommendations continue to evolve as scientists learn more about how immunity works over time and how the virus behaves seasonally.
How to Delete Your Fitbit Account Guide →
For people 65 and older, current CDC guidance recommends receiving an updated COVID vaccine annually, typically before fall and winter when respiratory viruses circulate more heavily. This is similar to the annual flu vaccine pattern most seniors are already familiar with. However, if you're significantly older (85+), immunocompromised, or living in a congregate setting like a nursing home, your doctor may recommend more frequent vaccination. Some research suggests people in these higher-risk groups benefit from doses spaced throughout the year rather than just one annual dose.
The timing recommendation reflects how immunity works. After receiving a vaccine, your immune system builds protection that peaks at a few weeks to a few months, then gradually declines. For seniors, this decline tends to happen faster than in younger people. Studies tracking thousands of vaccinated seniors found that protection against hospitalization remained strong through the winter season when one annual dose was received in the fall, but dropped more noticeably by spring and summer. This is the reasoning behind the seasonal timing.
If you received a COVID vaccine last year, you don't need to wait a full year to receive a new one—you can receive an updated vaccine as soon as it becomes available if your doctor recommends it. There's no penalty for spacing them closer together if circumstances change, such as if you're about to undergo surgery or enter a high-risk situation. Conversely, if you've been vaccinated multiple times, missing a single year won
This guide is for general information only and is not medical, financial, legal, or other professional advice. For decisions specific to your situation, consult a qualified professional. See our Editorial Policy.